A Preclinical Contract Research Organization Blog Compendium

Safety Pharmacology: Why Biology Changes the Study

Gene therapies, cell therapies, oligonucleotides, and other complex biologics don't behave like small molecules in a safety pharmacology study

Nonclinical Safety Studies for Novel Pet Food Ingredients

Between a promising ingredient and a product on the shelf stands a question every serious brand must answer with data.

Winning Before Kickoff: Gene Therapy Toxicology Planning

Just as football matches are won before kickoff, gene therapy toxicology studies succeed through preparation long before dosing begins.

Strengthening Gene Therapy GLP Studies with DRF Data

Before a sponsor commits to a pivotal GLP program, a well-designed dose range-finding study can provide critical information

In Vivo PK Studies Driving Faster Drug Development Decisions

One of the most common reasons promising drug candidates fail during development is not a lack of biological activity, but poor pharmacokinetic behavior.

5 Things Every Sponsor Should Know Before a Study Begins

The most successful studies don’t begin with the first dose, the first data point, or even the kickoff meeting. They begin much earlier, at the moment

Operational Excellence in AAV Biodistribution

Gene therapies, particularly those utilizing Adeno-associated viruses (AAV) vectors, have moved beyond the proof-of-concept phase into a

Lab Technicians: The Unsung Heroes Driving Research Success

At Attentive Science, our laboratory technicians are more than technical experts; they are collaborators and real-time problem-solvers

Preclinical Development Is a Strategy, Not Just a Service

Preclinical development is no longer a simple checkpoint on the path to the clinic; it is a strategic inflection point that can accelerate momentum